Personalis at 2021 SITC Annual Meeting: November 12-14, 2021

Poster Presentations

Charles Abbott

November 12-14, 2021 | Online

Abstract # 19
Poster Title: Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST
Presenter: Charles Abbott, PhD

Eric Levy

November 12-14, 2021 | Online

Poster # 75
Poster Title: Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome
Presenter: Eric Levy, PhD

Rachel Pyke

November 12-14, 2021 | Online

Poster # 79
Poster Title: Extensively validated HLA LOH algorithm demonstrates an association between HLA LOH and genomic instability 
Presenter: Rachel M. Pyke, PhD

Erin Newburn, PhD

Industry Sponsored Symposium Presentation | November 12 at 1:30 PM Eastern – Online

Erin Newburn, MS, PhD
Director, Field Application Scientist
Personalis, Inc.

Leveraging comprehensive genomic data for diagnostic capabilities and composite biomarker discovery in immunotherapy 

  • To enable the identification of composite biomarkers that combine tumor- and immune-related information from both DNA and RNA, we have developed the Personalis NeXT platform.
  • By utilizing the expansive feature set, individual analytes can be combined to construct composite biomarker scores that correlate with immunotherapy response.
  • In a cohort of 51 late-stage melanoma patients, the integration of neoantigen burden, HLA LOH, and APM mutational data formed a neoantigen-based composite neoantigen (NEOPS) that more accurately predicted response to checkpoint blockade than other markers such as TMB.
  • The platform has been analytically validated and optimized for use with limited FFPE tissue samples, making it ideal for both research and clinical applications.